It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...
Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $22 from $20 and keeps a Buy rating on the shares. The Miplyffa ...
Reports Q4 revenue $12M, consensus $8.93M. “2024 was a transformational year for Zevra. We emerged as a commercial stage company and are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback